168 related articles for article (PubMed ID: 37566192)
1. Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study.
Yang L; Lin H; Shen Y; Roy M; Albarracin C; Ding Q; Huo L; Chen H; Wei B; Bu H; Bedrosian I; Wu Y
Breast Cancer Res Treat; 2023 Nov; 202(1):23-32. PubMed ID: 37566192
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
3. Validation of prognostic significance of the proposed uniform classification framework in neuroendocrine neoplasms of the breast.
Yang L; Roy M; Lin H; Shen Y; Albarracin C; Huo L; Chen H; Wei B; Bedrosian I; Bu H; Wu Y
Breast Cancer Res Treat; 2021 Apr; 186(2):403-415. PubMed ID: 33528758
[TBL] [Abstract][Full Text] [Related]
4. Utility of Quantitative Metrics From Dual-Layer Spectral-Detector CT for Differentiation of Pancreatic Neuroendocrine Tumor and Neuroendocrine Carcinoma.
Wang Y; Hu X; Shi S; Song C; Wang L; Yuan J; Lin Z; Cai H; Feng ST; Luo Y
AJR Am J Roentgenol; 2022 Jun; 218(6):999-1009. PubMed ID: 35043668
[No Abstract] [Full Text] [Related]
5. Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis.
Komiyama S; Okusaka T; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Morizane C; Ueno H; Sukeda A; Mizui T; Takamoto T; Nara S; Ban D; Esaki M; Hiraoka N; Shimada K
Intern Med; 2024 Apr; 63(7):891-901. PubMed ID: 37612088
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
7. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
8. Correlation of World Health Organization 2010 Classification for Gastroenteropancreatic Neuroendocrine Neoplasms with the Prognosis of Ovarian Neuroendocrine Neoplasms: Kansai Clinical Oncology Group-Protocol Review Committee/Intergroup Study.
Kai K; Nasu K; Nishida H; Daa T; Shikama A; Shiozaki T; Kurakazu M; Yano M; Imamura Y; Tokunaga H; Tasaki K; Iida Y; Yamada Y; Morisawa H; Nakagawa S; Fujimoto E; Tsuruta T; Matsumoto H; Arakawa A; Nonaka M; Takano H; Ushiwaka T; Mori T; Ito K; Motohashi T; Teramoto N; Yamada T
Neuroendocrinology; 2021; 111(4):320-329. PubMed ID: 32097950
[TBL] [Abstract][Full Text] [Related]
9. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database.
Wang J; Wei B; Albarracin CT; Hu J; Abraham SC; Wu Y
BMC Cancer; 2014 Mar; 14():147. PubMed ID: 24589259
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
11. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics of gastric neuroendocrine neoplasms: A comprehensive analysis.
Zi M; Ma Y; Chen J; Pang C; Li X; Yuan L; Liu Z; Yu P
Cancer Med; 2024 Feb; 13(4):e7011. PubMed ID: 38457192
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study.
Zhang P; Wang W; Lu M; Zeng C; Chen J; Li E; Tan H; Wang W; Yu X; Tang Q; Zhao J; Shen L; Li J
Cancer Med; 2018 Sep; 7(9):4361-4370. PubMed ID: 30062861
[TBL] [Abstract][Full Text] [Related]
15. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
[TBL] [Abstract][Full Text] [Related]
16. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.
Li MX; Li QY; Xiao M; Wan DL; Chen XH; Zhou L; Xie HY; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):538-545. PubMed ID: 30981633
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine neoplasms of the breast: diagnostic agreement and impact on outcome.
Metovic J; Cascardi E; Uccella S; Maragliano R; Querzoli G; Osella-Abate S; Pittaro A; La Rosa S; Bogina G; Cassoni P; Marchiò C; Sapino A; Castellano I; Papotti M
Virchows Arch; 2022 Dec; 481(6):839-846. PubMed ID: 36243799
[TBL] [Abstract][Full Text] [Related]
18. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
[TBL] [Abstract][Full Text] [Related]
19. Volumetric parameters from [
Langen Stokmo H; Aly M; Bowitz Lothe IM; Borja AJ; Mehdizadeh Seraj S; Ghorpade R; Miao X; Hjortland GO; Malinen E; Sorbye H; Werner TJ; Alavi A; Revheim ME
J Neuroendocrinol; 2022 Jul; 34(7):e13170. PubMed ID: 35729738
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]